Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-5,645
Closed -$407K 749
2024
Q4
$407K Sell
5,645
-7,580
-57% -$592K 0.13% 284
2024
Q3
$1.08M Sell
13,225
-15,179
-53% -$1.21M 0.25% 69
2024
Q2
$2.11M Buy
+28,404
New +$2.13M 0.37% 26
2024
Q1
Sell
-28,154
Closed -$2.01M 907
2023
Q4
$2.01M Buy
28,154
+6,981
+33% +$486K 0.94% 3
2023
Q3
$1.47M Buy
21,173
+9,573
+83% +$723K 0.47% 37
2023
Q2
$939K Buy
11,600
+6,200
+115% +$507K 0.49% 46
2023
Q1
$436K Sell
5,400
-1,200
-18% -$96.6K 0.66% 45
2022
Q4
$494K Buy
+6,600
New +$470K 0.36% 121

Other funds holding HOLX

Sherbrooke Park Advisers's HOLX Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Hologic (HOLX) in Q1 2025, closing a stake of 5,645 shares — an estimated $407K sold.

Sherbrooke Park Advisers first reported a position in HOLX in Q4 2022 and held it in 8 quarters. The position peaked at $2.11M in Q2 2024. 706 funds tracked by Wall St. Rank hold HOLX as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Hologic position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 5,645 Hologic shares in Q1 2025, an estimated $407K.
  • Sherbrooke Park Advisers first reported a position in Hologic in Q4 2022 and held it in 8 quarters.
  • Sherbrooke Park Advisers's Hologic position peaked at $2.11M in Q2 2024.
  • 706 funds tracked by Wall St. Rank held Hologic as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.